Douglas Hamilton, M.D. Offers Patients a Permanent Solution

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Douglas Hamilton, M.D. Offers Patients a Permanent Solution to Acne Scars with Bellafill

Los Angeles, Dec. 10, 2015 (GLOBE NEWSWIRE) -- Assistant Clinical Professor of Dermatology at UCLA Douglas Hamilton, M.D. is among the select physicians to offer the first FDA-approved filler for the treatment of acne scars.  Bellafill (formerly Artefill) is injected beneath the acne scar to raise the skin by inducing the development of the patient's own skin collagen. Unlike other popular fillers, such as Restylane and Juvederm, which begin to wear off the moment they are injected, Bellafill offers patients a permanent solution that improves over time.

Dr. Hamilton, who treats patients at both his Beverly Hills and Woodland Hills, California offices, acted as lead investigator in the FDA trials that first obtained approval for the use of Bellafill/Artefill in the country. Additionally, he was the only U.S. dermatologist invited to appear on behalf of the manufacturer at the FDA approval meeting in Maryland.

"The improvement is seen immediately and most scars become virtually undetectable," said Dr. Hamilton. "Then over a period of about three months, the temporary cow collagen in Bellafill is gradually replaced by an equal volume of the patient's own natural collagen. This is due to the presence of a collagen stimulant (PMMA) present in the filler. I recommend a second treatment at no charge be performed at three months after the first to perfect the result."

The embarrassment and blight of acne scarring is not a new phenomenon. Prior treatments have included deep dermabrasion sanding, which produces bleeding and scabbing of the skin, and in the 1990s, laser resurfacing with carbon dioxide and erbium lasers were also popular.  In addition to providing only moderate results, all of these treatments yielded a downtime for healing of seven to 10 days, as well as possible complications of color loss. Though more recently the Fraxel laser seemed a promising solution to acne scars, many patients' skin remained resistant.

"Bellafill is, in fact, a biostimulant, which means patients' scarring will continue to improve over the next couple of years," said Dr. Hamilton, who not only treated the first U.S. patients with this product, but also published the first medical journal article about the results. "Many patients do not require any further treatments after the first two. However, the placement of this product must be precise; problems can arise from injections administered by inexperienced physicians."

The requirement for training and expertise exceeds that needed with other fillers and for that reason, Bellafill is generally only performed by highly experienced physicians. Dr. Hamilton was one of the authors of a medical journal publication assessing the duration of Bellafill at five years after treatment and was the only investigator to perform a 12 year assessment for Suneva: both of these were in the treatment of expression lines/wrinkles.

"Our experience in both the treatment of wrinkles and acne scars plainly shows that the effects of Bellafill are permanent, though the FDA apparently has a much longer timeframe requirement than 12 years to allow the term 'permanent' to be used in marketing," said Dr. Hamilton. "This is a wonderful advance in cosmetic medicine that was developed by the brilliant German plastic surgeon, Gottfried Lemperle, whom I am proud to call a friend. It is not designed for use in OMG Spa: this is real medicine doing what we in medicine were called to do, i.e., make people feel and look better."

For more information or to schedule an appointment with Dr. Hamilton, please visit drhamilton.com or call (310) 275-6400.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Workhorse Group Battles Nasdaq Compliance Amid Financial Woes

Updated Category News Views 87

Workhorse Group Faces Nasdaq Compliance Challenges Workhorse Group Inc (NASDAQ: WKHS), a manufacturer in the electric vehicle sector, has recently been issued a notice by the Nasdaq Stock Market regarding its non-compliance with the minimum bid price requirement. The pressing issue arises from the company's common stock trading below the $1.00 mark for a continuous period...

Continue Reading
Investors Have a Deadline to Join NET Power Class Action

Updated Category News Views 293

Investors Have a Deadline to Join NET Power Class Action In a significant turn of events, Kahn Swick & Foti, LLC advises investors who’ve incurred losses exceeding $100,000 in NET Power Inc. to take action. If you are among those affected, the time is critical. You have until June 17, 2025 to file your lead plaintiff application in this securities class action lawsuit...

Continue Reading
New Developments in Borregaard ASA's Share Transactions

Updated Category News Views 152

Insight into Recent Share Purchases at Borregaard ASA Recently, significant transactions have emerged within Borregaard ASA that are noteworthy for investors and stakeholders alike. Tove Andersen, a dedicated member of the board, made headlines by acquiring 2,000 shares at a price of NOK 187.92 each. This purchase marks a decisive move, increasing her total holdings to...

Continue Reading
Guaranteed Roof Enhances Commercial Roofing Options in NC

Updated Category News Views 136

Guaranteed Roof Enhances Commercial Roofing Options in North Carolina Guaranteed Roof, recognized for its expertise in roof rejuvenation and replacement services, is excited to announce a major enhancement to its commercial division. This initiative strongly emphasizes the utilization of FAR Coatings, a cutting-edge solution for flat and low-slope roofs. By leveraging...

Continue Reading
Key Details for Sage Therapeutics, Inc. Investors Ahead of Deadline

Updated Category News Views 38

Understanding the Class Action for Sage Therapeutics, Inc. As a diligent investor, knowing your rights is crucial, especially when involved with companies like Sage Therapeutics, Inc. (NASDAQ: SAGE). If you purchased securities between specific dates, it’s essential to pay attention to upcoming deadlines. The Importance of the Deadline The Rosen Law Firm, a leading...

Continue Reading